Languages

• English, fluent.

Publications

• Colonna S, Halwani A, Ying J, Buys S & Sweeney C (2015). Women with breast cancer in the Veterans Health Administration: demographics, breast cancer characteristics, and trends. Medical care. Vol. 53, S149-55. Published, 03/01/2015.
• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA & Armand P (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. (pp. 311-9). Vol. 372. The New England journal of medicine. Published, 01/01/2015.
• Nelson SD, Lu CC, Teng CC, Leng J, Cannon GW, He T, Zeng Q, Halwani A & Sauer B (2015). The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiology and drug safety. Vol. 24, 86-92. Published, 01/01/2015.
• Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S & Bishop GA (2014). A new model of LMP1-MYC interaction in B cell lymphoma. Leukemia & lymphoma. Vol. 55, 2917-23. Published, 12/01/2014.
• Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA & Janz S (2013). Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. Biochemical and biophysical research communications. Vol. 436, 660-5. Published, 07/01/2013.
• Halwani AS & Link BK (2011). Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert review of anticancer therapy. Vol. 11, 443-55. Published, 03/01/2011.
• Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R & Weiner GJ (2008). A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. Vol. 14, 6697-703. Published, 10/01/2008.